Nrg-Br004- A Randomized, Double-Blind, Phase III Trial Of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab Or Placebo In First-Line Her2-Positive Metastatic Breast Cancer
Posted Date: Sep 25, 2019
- Investigator: Mahmoud Charif
- Specialties: Breast Cancer, Cancer
- Type of Study: Drug
Patients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36, and atezolizumab IV /placebo over 60 minutes on days 1 and 22. Cycles for pertuzumab, trastuzumab and atezolizumab repeat every 6 weeks and treatment with paclitaxel repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional 3 cycles of paclitaxel in the absence of progression at the investigator's discretion.
Criteria:
Her2 + Metastatic Or Recurrent Breast Cancer, Trial Of Immunotherapy With Std Of Care Antiher 2Neu Therapy
Keywords:
Stage Iv Or Recurrent, Her2/Neu Positive, Immunotherapy
For More Information:
Laura Bundus
51358478476
bundusla@ucmail.uc.edu